Cornbleet M A, Chessells J M
Br Med J. 1978 Jul 8;2(6130):104-6. doi: 10.1136/bmj.2.6130.104.
The outcome after bone-marrow relapse was assessed in 53 children with acute lymphoblastic leukaemia (ALL). Twenty-five out of 37 children (67%) whose first remission ended in relapse during treatment (group A) achieved a second remission, as did 15 out of 16 (94%) who relapsed after treatment had been stopped (group B). Nevertheless, the median duration of second remission was only 12 weeks in group A and 35 weeks in group B. The median survival from time of relapse was 32 weeks in group A and 75 weeks in group B. It is concluded that marrow relapse is equally serious whether it occurs during treatment or after treatment has been stopped, and that most children with ALL have a single chance of cure at the time of diagnosis.
对53例急性淋巴细胞白血病（ALL）患儿骨髓复发后的转归进行了评估。37例在治疗期间首次缓解以复发告终的患儿（A组）中有25例（67%）获得了第二次缓解，16例在治疗停止后复发的患儿（B组）中有15例（94%）获得了第二次缓解。然而，A组第二次缓解的中位持续时间仅为12周，B组为35周。从复发时起的中位生存期，A组为32周，B组为75周。得出的结论是，骨髓复发无论发生在治疗期间还是治疗停止后都同样严重，并且大多数ALL患儿在诊断时只有一次治愈的机会。
